Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

This study will be a randomized, open-label, 3-period, 3-treatment, single dose, single-center, crossover study. Eighteen healthy male and female subjects will be randomized in this study to ensure that at least 12 subjects are evaluable. A subject will be considered to be evaluable if the subject completes all 3 Treatment Periods with no important protocol deviations. Subjects will be randomized to 1 of 6 treatment sequences and will receive each of the 3 single dose treatments of AZD1402 listed below. * Treatment A: Dose A estimated delivered dose of AZD1402 nebuliser solution administered via a nebuliser. * Treatment B: Dose B estimated delivered dose of AZD1402 inhalation powder administered via an inhaler. * Treatment C: Dose C estimated delivered dose of AZD1402 inhalation powder administered via an inhaler. The study will comprise of: * A Screening Period of up to 28 days before the first administration of AZD1402. * Three Treatment Periods during which subjects will be resident at the Clinical Unit from the day before dosing with AZD1402 (Day -1) until at least 48 hours after dosing and discharged on Day 3. * A Follow-up Visit 10 to 12 days after the last administration of AZD1402 in Treatment Period 3. Each Treatment Period will be separated by a minimum washout period of 5 days between doses. All subjects will sign an Informed Consent Form before they participate in any specific study related procedures. Subjects will attend a Screening Visit within 28 days before receiving their first dose of AZD1402. If they are eligible, they will return for Treatment Period 1 when they will have baseline assessments and receive 1 of 3 treatments in a randomized order. For each Treatment Period, the subjects will receive a single dose of Investigational Medicinal Product (IMP) in the morning of Day 1 and have further assessments for 48 hours after dosing.